Harwood Advisory Group LLC Acquires 945 Shares of Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Harwood Advisory Group LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 1.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 56,009 shares of the biopharmaceutical company’s stock after acquiring an additional 945 shares during the period. Harwood Advisory Group LLC’s holdings in Pfizer were worth $2,426,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Fisher Asset Management LLC raised its holdings in shares of Pfizer by 3.7% in the second quarter. Fisher Asset Management LLC now owns 44,133,251 shares of the biopharmaceutical company’s stock worth $1,911,852,000 after buying an additional 1,559,405 shares during the last quarter. California Public Employees Retirement System raised its holdings in shares of Pfizer by 14.0% in the fourth quarter. California Public Employees Retirement System now owns 20,333,138 shares of the biopharmaceutical company’s stock worth $887,541,000 after buying an additional 2,504,336 shares during the last quarter. Sanders Capital LLC raised its holdings in shares of Pfizer by 3.3% in the second quarter. Sanders Capital LLC now owns 18,749,080 shares of the biopharmaceutical company’s stock worth $910,953,000 after buying an additional 606,700 shares during the last quarter. APG Asset Management N.V. raised its holdings in shares of Pfizer by 1.4% in the fourth quarter. APG Asset Management N.V. now owns 16,360,380 shares of the biopharmaceutical company’s stock worth $624,704,000 after buying an additional 228,300 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Pfizer by 1.2% in the fourth quarter. Rhumbline Advisers now owns 9,449,884 shares of the biopharmaceutical company’s stock worth $412,487,000 after buying an additional 113,506 shares during the last quarter. 71.58% of the stock is owned by institutional investors.

PFE has been the subject of a number of research analyst reports. Bank of America cut shares of Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. Credit Suisse Group reaffirmed a “neutral” rating on shares of Pfizer in a report on Monday, August 12th. Goldman Sachs Group reaffirmed a “buy” rating and issued a $49.00 price target on shares of Pfizer in a report on Monday, June 17th. Morgan Stanley cut shares of Pfizer from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $48.00 to $40.00 in a report on Tuesday, July 30th. Finally, Barclays reaffirmed a “hold” rating and issued a $41.00 price target on shares of Pfizer in a report on Thursday, May 9th. Fourteen analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $46.67.

Shares of Pfizer stock traded down $0.74 during trading on Friday, hitting $34.34. 20,323,181 shares of the company’s stock were exchanged, compared to its average volume of 35,302,192. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. The business has a 50-day simple moving average of $39.60 and a 200-day simple moving average of $41.43. Pfizer Inc. has a 52-week low of $33.97 and a 52-week high of $46.47. The stock has a market capitalization of $194.03 billion, a price-to-earnings ratio of 11.45, a PEG ratio of 2.80 and a beta of 0.63.

Pfizer (NYSE:PFE) last issued its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The firm had revenue of $13.26 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter last year, the company posted $0.77 earnings per share. The firm’s revenue was down 1.5% compared to the same quarter last year. On average, equities analysts anticipate that Pfizer Inc. will post 2.8 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd will be issued a dividend of $0.36 per share. The ex-dividend date is Thursday, August 1st. This represents a $1.44 annualized dividend and a dividend yield of 4.19%. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

In related news, EVP Frank A. Damelio sold 153,184 shares of the firm’s stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the sale, the executive vice president now owns 489,647 shares in the company, valued at $21,588,536.23. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 30,000 shares of the firm’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the sale, the insider now owns 80,094 shares in the company, valued at approximately $3,524,136. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: Do investors pay a separate front-end load every time they buy additional shares?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cognizant Technology Solutions  Downgraded by ValuEngine
Cognizant Technology Solutions Downgraded by ValuEngine
Cohu  Raised to “Hold” at BidaskClub
Cohu Raised to “Hold” at BidaskClub
Exelixis  Cut to “Strong Sell” at ValuEngine
Exelixis Cut to “Strong Sell” at ValuEngine
BidaskClub Upgrades First Midwest Bancorp  to “Sell”
BidaskClub Upgrades First Midwest Bancorp to “Sell”
ValuEngine Upgrades Blackbaud  to “Strong-Buy”
ValuEngine Upgrades Blackbaud to “Strong-Buy”
Anavex Life Sciences  Upgraded to “Buy” by ValuEngine
Anavex Life Sciences Upgraded to “Buy” by ValuEngine


 
© 2006-2019 Zolmax.